Biocon Ltd
NSE:BIOCON
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
245.75
391.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biocon Ltd
Biocon Ltd
Total Liabilities & Equity
Biocon Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biocon Ltd
NSE:BIOCON
|
Total Liabilities & Equity
₹560.7B
|
CAGR 3-Years
44%
|
CAGR 5-Years
34%
|
CAGR 10-Years
25%
|
|
|
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
|
Total Liabilities & Equity
₹1.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Transgene Biotek Ltd
BSE:526139
|
Total Liabilities & Equity
₹1.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Z
|
Zenotech Laboratories Ltd
BSE:532039
|
Total Liabilities & Equity
₹1.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
Hester Biosciences Ltd
NSE:HESTERBIO
|
Total Liabilities & Equity
₹6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Panacea Biotec Ltd
NSE:PANACEABIO
|
Total Liabilities & Equity
₹12.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Biocon Ltd
Glance View
In the bustling world of biotechnology, Biocon Ltd. stands as a beacon of innovation, rooted in its Indian origins yet extending its influence globally. Founded in 1978 by Kiran Mazumdar-Shaw, a visionary with a degree in fermentation science, Biocon began its journey as a maker of enzymes before transforming into a formidable force in biopharmaceuticals. This transformation was driven by the company's emphasis on research and development, leading to groundbreaking advancements in biosimilars, generics, and novel biotherapeutics. These products cater to critical areas such as oncology, diabetes, and autoimmune diseases. The company's success hinges on its ability to blend scientific rigor with entrepreneurial flair, enabling it to deliver high-quality, cost-effective solutions in a market traditionally dominated by Western giants. Biocon's revenue model is intricately woven from various strands of its expansive portfolio. A significant chunk emerges from its biologics division, where it manufactures biosimilars that serve as cost-friendly alternatives to expensive biologic drugs. Simultaneously, the company capitalizes on its expertise in small molecule APIs and branded formulations, which are integral to its generics business. Furthermore, collaborations and partnerships with global pharmaceutical companies amplify its reach, facilitating market access and regulatory navigation. Through these strategic undertakings, Biocon not only bolsters its financial performance but also reinforces its commitment to enhancing healthcare affordability and accessibility across the globe.
See Also
What is Biocon Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
560.7B
INR
Based on the financial report for Sep 30, 2024, Biocon Ltd's Total Liabilities & Equity amounts to 560.7B INR.
What is Biocon Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
25%
Over the last year, the Total Liabilities & Equity growth was 3%. The average annual Total Liabilities & Equity growth rates for Biocon Ltd have been 44% over the past three years , 34% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
